AnaptysBio, Inc. (ANAB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

AnaptysBio, Inc. (ANAB) closed at USD 46.67 on 2026-10-14, a change of +93.6 % over the past year, with a market capitalization of USD 1.46B.

AnaptysBio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

AnaptysBio, Inc. key figures

Previous close

USD 46.67 (2026-10-14)

1-year change

+93.6 %

Market cap

USD 1.46B

Enterprise value

USD 1.56B

P/E ratio (trailing)

-47.29

P/E ratio (forward)

9.61

EPS (trailing)

-1.03

EPS (forward)

5.07

PEG ratio

n/a

Price to book

136.83

Revenue growth

23.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.96

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About AnaptysBio, Inc.

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for AnaptysBio, Inc. and compare it with other stocks.